(Q36858013)

16 August 2017

The clinical implications of sunitinib-induced hypothyroidism: a prospective evaluation (English)

1 reference

16 August 2017

P Wolter

1

1 reference

16 August 2017

C Stefan

2

1 reference

16 August 2017

B Decallonne

3

1 reference

16 August 2017

H Dumez

4

1 reference

16 August 2017

M Bex

5

1 reference

16 August 2017

P Carmeliet

6

1 reference

16 August 2017

P Schöffski

7

1 reference

16 August 2017

language of work or name

English

0 references

publication date

1 August 2008

1 reference

British Journal of Cancer

16 August 2017

1 reference

16 August 2017

99

1 reference

16 August 2017

3

1 reference

16 August 2017

448-454

1 reference

https://scigraph.springernature.com/pub.10.1038/sj.bjc.6604497

16 August 2017

0 references

cites work

Multicenter, phase II trial of sunitinib in previously treated, advanced non-small-cell lung cancer

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2527784

Sunitinib induces hypothyroidism in advanced cancer patients and may inhibit thyroid peroxidase activity

29 September 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2527784

Aspects of treatment of subclinical hypothyroidism.

29 September 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2527784

Sunitinib: a VEGF and PDGF receptor protein kinase and angiogenesis inhibitor

29 September 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2527784

Approval summary: sunitinib for the treatment of imatinib refractory or intolerant gastrointestinal stromal tumors and advanced renal cell carcinoma

29 September 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2527784

Sunitinib: from rational design to clinical efficacy

29 September 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2527784

Efficacy and safety of sunitinib in patients with advanced gastrointestinal stromal tumour after failure of imatinib: a randomised controlled trial

29 September 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2527784

High prevalence of hypothyroidism in male patients with cutaneous melanoma

29 September 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2527784

Emerging role of tyrosine kinase inhibitors in the treatment of advanced renal cell cancer: a review.

29 September 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2527784

Safety, pharmacokinetic, and antitumor activity of SU11248, a novel oral multitarget tyrosine kinase inhibitor, in patients with cancer

29 September 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2527784

Hypothyroidism in the elderly: pathophysiology, diagnosis and treatment.

29 September 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2527784

Thyroid disease: pathophysiology and diagnosis

29 September 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2527784

Subclinical thyroid disease: scientific review and guidelines for diagnosis and management

29 September 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2527784

Activity of SU11248, a multitargeted inhibitor of vascular endothelial growth factor receptor and platelet-derived growth factor receptor, in patients with metastatic renal cell carcinoma

29 September 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2527784

Phase II study of sunitinib malate, an oral multitargeted tyrosine kinase inhibitor, in patients with metastatic breast cancer previously treated with an anthracycline and a taxane

27 June 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2527784

Thyroid function test abnormalities in patients with metastatic renal cell carcinoma treated with sorafenib

4 September 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2527784

Phase II trial of sunitinib in patients with metastatic colorectal cancer after failure of standard therapy

4 September 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2527784

Food and Drug Administration drug approval summary: Sunitinib malate for the treatment of gastrointestinal stromal tumor and advanced renal cell carcinoma.

4 September 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2527784

Hypothyroidism after sunitinib treatment for patients with gastrointestinal stromal tumors.

4 September 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2527784

VEGF-dependent plasticity of fenestrated capillaries in the normal adult microvasculature

4 September 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2527784

Cellular changes in normal blood capillaries undergoing regression after inhibition of VEGF signaling

4 September 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2527784

Autoimmune thyroid diseases in women with breast cancer and colorectal cancer.

4 September 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2527784

Do iodine-containing contrast media induce clinically relevant changes in thyroid function parameters of euthyroid patients within the first week?

4 September 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2527784

High prevalence of hypothyroidism among patients with cutaneous melanoma.

4 September 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2527784

American Thyroid Association guidelines for use of laboratory tests in thyroid disorders

4 September 2018

1 reference

12 December 2020

Tyrosine kinase inhibitors causing hypothyroidism in a patient on levothyroxine

1 reference

12 December 2020

Hypothyroidism in patients with metastatic renal cell carcinoma treated with sunitinib

1 reference

12 December 2020

Sunitinib and Hypothyroidism

1 reference

12 December 2020

Re: Hypothyroidism in patients with metastatic renal cell carcinoma treated with sunitinib

1 reference

12 December 2020

A Novel Tyrosine-Kinase Selective Inhibitor, Sunitinib, Induces Transient Hypothyroidism by Blocking Iodine Uptake

1 reference

12 December 2020

Identifiers

DOI

10.1038/SJ.BJC.6604497

1 reference

Dimensions Publication ID

16 August 2017

0 references

1 reference

16 August 2017

1 reference